



## **Developing Pediatric Treatments for COVID-19**

### **Virtual Workshop**

**May 28, 2020 – 10 am-12:30 pm**

#### **Moderators**

**Edward Connor, MD, MBE**, Founder and Chairman, I-ACT for Children

**Susan McCune, MD**, Director, Office of Pediatric Therapeutics, US Food and Drug Administration

#### **Agenda**

**10-10:10 am**

**Welcome**

***Laura Gordon, Chief Executive Officer, I-ACT for Children***

**Introduction: Focusing on COVID-19 Research and Children**

***Edward Connor, MD, MBE***

#### **I. Background**

**10:10-10:25 am**

**COVID-19 in Pediatric Populations**

- ***Collin Hovinga, PharmD***, SVP, Clinical & Scientific Development, I-ACT for Children
- ***Seth Kuranz***, Principal Epidemiologist, TriNetX

**10:25-10:35 am**

**Diagnosis, Clinical Presentation and Outcomes of Children with COVID-19**

***Roberta DeBiasi, MD, MS***, Chief, Infectious Diseases, Children's National Medical Center

#### **II. Approach to Pediatric Therapeutics Development in COVID-19**

**10:35-10:55 am**

**Current State of Drug/Biologics Development**


- ***Gary Noel, MD***, Chief Medical Officer, I-ACT for Children
- ***Lynne Yao, MD***, Director, Division of Pediatric and Maternal Health, Urologic and Reproductive Medicine; Center for Drug Evaluation and Research, US Food and Drug Administration

**10:55-11:05 am**

**Innovative Methods for Conducting Pediatric Clinical Trials**

***Lily Mulugeta, PharmD***, Associate Director for Science, Division of Pediatric and Maternal Health, US Food and Drug Administration





**11:05-11:25 am**

**Antiviral Drug Development: Drugs and Biologics**

- **Cheryl Pikora, MD, PhD**, Senior Medical Director, Global Clinical Research, Pediatric HIV and Pediatric Emerging Viruses Project Team Lead, Gilead Sciences, Inc
- **Yodit Belew, MD**, Senior Medical Officer, Division of Antiviral Products, Center for Drug Evaluation and Research, US Food and Drug Administration

**11:25-11:50 am**

**Development of Immunomodulators**

- **Wallace Crandall, MD, MMM**, Medical Fellow/Senior Medical Leader for Pediatric Immunology, Eli Lilly and Company
- **Nikolay Nikolov, MD**, Acting Director, Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, US Food and Drug Administration

**11:50 am-Noon**

**Ethical considerations**

**John Lantos, MD**, Professor of Pediatrics, University of Missouri–Kansas City School of Medicine, Director, Children's Mercy Bioethics Center, Children's Mercy Hospital

**III. Panel Discussion and Q&A**

**Noon-12:25 pm**

Moderator: **Susan McCune, MD**

**Panelists (in addition to above presenters)**

- **Keira Sorrells**, Founder & Executive Director, NICU Parent Network
- **John Bradley, MD**, Medical Director, Division of Infectious Diseases, Rady Children's Hospital-San Diego
- **Octavio Ramilo, MD**, Henry G. Cramblett Chair in Infectious Diseases and Professor of Pediatrics at the Ohio State University College of Medicine; Chief of Infectious Diseases at Nationwide Children's Hospital
- **Aaron C Pawlik, PhD**, Chief, Obstetric and Pediatric Pharmacology and Therapeutics Branch; Division of Extramural Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH

**12:25-12:30 pm**

**Closing Remarks**

**Ed Connor, MD, MBE**

**Susan McCune, MD**

---